
STATE OF WISCONSIN,)	
)	
Plaintiff,)	Case No.: 04-CV-1709
)	
v.)	
)	
ABBOTT LABORATORIES, et. al.,)	
)	
Defendants.)	

**AMGEN INC.'S ANSWERS AND OBJECTIONS TO
PLAINTIFF'S FIFTH SET OF INTERROGATORIES TO ALL DEFENDANTS**

Pursuant to Wis. Stat. §§ 804.01 and 804.08, defendant Amgen Inc. ("Amgen"), by its attorneys, answers and objects to Plaintiff's Fifth Set of Interrogatories to All Defendants ("Interrogatory No. 13") as follows:

PRELIMINARY STATEMENT

1. The answer and objections to Interrogatory No. 13 are made solely for the purposes of this action. Amgen's answer is subject to all objections as to competence, relevance, materiality, propriety, and admissibility, and to any and all other objections that may be applicable at a trial or other hearing or proceeding, all of which objections and grounds are expressly reserved and may be interposed at the time of trial.

2. Amgen's answer and objections shall not be deemed to constitute admissions:
- a. that any particular document or thing exists, is relevant, non-privileged, or admissible in evidence; or
 - b. that any statement or characterization in Interrogatory No. 13 is accurate or complete.

3. Amgen's answer is made based upon the usual interpretation of words contained in Interrogatory No. 13 since no definitions or instructions have been provided.

4. Amgen is responding on its own behalf, and not on behalf of Immunex Corporation, a wholly-owned subsidiary, which has been named as a separate defendant in these proceedings and is separately represented by counsel.

RESPONSE TO INTERROGATORY NO. 13


INTERROGATORY NO. 13: For each calendar year from 1993 to the present, identify the following:

- (a) the gross annual sales of your drugs in the United States; and
- (b) the percentage of the gross annual sales of your drugs in the United States that is attributable to Medicaid patients, *i.e.*, that results from sales to (or stated differently, reimbursement by) state Medicaid programs.

RESPONSE: Amgen objects to Interrogatory No. 13 on the grounds that it is overly broad, unduly burdensome, and the phrases “gross annual sales” and “attributable to Medicaid patients” are vague and ambiguous. Amgen also objects to Interrogatory No. 13 on the grounds that it seeks information that is not relevant to the issues in this action and not reasonably calculated to lead to the discovery of admissible evidence, such as: (1) information for Amgen products not at issue in this case; (2) information for products purchased outside Wisconsin; (3) information for products not reimbursed by Wisconsin Medicaid; and (4) information for periods after the filing of the initial complaint in this action. Amgen further objects to Interrogatory No. 13 to the extent it seeks information that is a matter of public record, is equally available to Plaintiff, or is already in the possession of Plaintiff. Amgen also objects to Interrogatory No. 13 to the extent it seeks to expand upon or alter Amgen’s obligations under the Wisconsin statutes.

Notwithstanding these objections and without waiving them, Amgen answers that it has already produced data from which the answer to part of Interrogatory No. 13 may be obtained.

December 10, 2007


Joseph H. Young
Steven F. Barley
Jennifer A. Walker
HOGAN & HARTSON, LLP
111 S. Calvert St., Suite 1600
Baltimore, MD 21202
410-659-2700 (phone)
410-539-6981 (fax)

William M. Conley
Jeffrey A. Simmons
FOLEY & LARDNER
150 East Gilman Street
Verex Plaza
Madison, WI 53703
Telephone: (608) 257-5035
Facsimile: (608) 258-4258

Attorneys for Amgen Inc.

Certificate of Service

I certify that on December 10, 2007 a true and correct copy of the foregoing was served on all counsel of record by Lexis Nexis File & Serve®.

/s/ Jennifer A. Walker